Danielle Riley
University of Iowa
10 Papers
6 Citations
Danielle Riley is an academic researcher from University of Iowa. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
Comparative effectiveness of aspirin dosing in cardiovascular disease.
W. Schuyler Jones,Hillary Mulder,Lisa M. Wruck,Michael J. Pencina,Sunil Kripalani,Daniel Muñoz,David L. Crenshaw,Mark B. Effron,Richard N. Re,Kamal Gupta,R. David Anderson,Carl J. Pepine,Eileen M. Handberg,Brittney R. Manning,Sandeep Jain,Saket Girotra,Danielle Riley,Darren A. DeWalt,Jeff Whittle,Ythan H. Goldberg,Véronique L. Roger,Rachel Hess,Catherine P. Benziger,Peter Farrehi,Li Zhou,Daniel E. Ford,Kevin Haynes,Jeffrey J. VanWormer,Kirk U. Knowlton,Jennifer L. Kraschnewski,Tamar S. Polonsky,Dan J. Fintel,Faraz S. Ahmad,James C. McClay,James R. Campbell,Douglas S. Bell,Gregg C. Fonarow,Steven M. Bradley,Anuradha Paranjape,Matthew T. Roe,Holly Robertson,Lesley H. Curtis,Amber G. Sharlow,Lisa G. Berdan,Bradley G. Hammill,Debra F. Harris,Laura G. Qualls,Guillaume Marquis-Gravel,Madelaine Faulkner Modrow,Gregory M. Marcus,Thomas W Carton,Elizabeth Nauman,Lemuel R. Waitman,Abel N. Kho,Elizabeth Shenkman,Kathleen M. McTigue,Rainu Kaushal,Frederick A. Masoudi,Elliott M. Antman,Desiree R. Davidson,Kevin Edgley,James G. Merritt,Linda S. Brown,Doris N. Zemon,Thomas E. McCormick,Jacqueline D. Alikhaani,Kenneth C. Gregoire,Russell L. Rothman,Robert A. Harrington,Adrian F. Hernandez,Oana A. Sandu +70 more
TL;DR: The appropriate dose of aspirin to lower the risk of death, myocardial infarction, and stroke and to minimize major bleeding in patients with established atherosclerotic cardiov... as discussed by the authors.
191
Upper extremity disability and quality of life after breast cancer treatment in the Greater Plains Collaborative clinical research network
Elizabeth A. Chrischilles,Danielle Riley,Elena M. Letuchy,Linda A Koehler,Joan M. Neuner,Cheryl Jernigan,Brian M. Gryzlak,Neil A. Segal,Neil A. Segal,Bradley D. McDowell,Brian J. Smith,Sonia L. Sugg,Jane M. Armer,Ingrid Lizarraga +13 more
TL;DR: A large portion of treatment effect on QoL is mediated by UED, and rehabilitation practices that prevent and alleviate UED are likely to improveQoL for breast cancer survivors.
The association of socioeconomic status with receipt of neoadjuvant chemotherapy
Joan M. Neuner,Amanda L. Kong,Ann Blaes,Danielle Riley,Elizabeth A. Chrischilles,Alicia J. Smallwood,Ingrid Lizarraga,Mary C. Schroeder +7 more
TL;DR: Lower income was strongly associated with less receipt of neoadjuvant chemotherapy among women with histologically confirmed invasive stage I–III breast cancer and this pattern has the potential to contribute to breast cancer outcome disparities.
17
Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial
Guillaume Marquis-Gravel,Holly Robertson,W. Schuyler Jones,W. Schuyler Jones,Danielle Riley,Daniel E. Ford,David Crenshaw,Yvonne Joosten,Lindsey Rudov,Adrian F. Hernandez,Adrian F. Hernandez,Rachel Hess +11 more
TL;DR: The ADAPTABLE randomized controlled trial as discussed by the authors evaluated the comparative effectiveness of two doses of aspirin widely used for secondary prevention in 15,000 patients with an established history of atherosclerotic cardiovascular disease.
Abstract 14192: Effect of Aspirin Dosing in Patients Treated With P2Y12 Inhibitors for Secondary Prevention of Cardiovascular Events
Saket Girotra,Amanda Stebbins,Lisa Wruck,Danielle Riley,Sunil Kripalani,Daniel Muñoz,Mark B. Effron,Kamal Gupta,Jeff Whittle,Catherine P. Benziger,Li Zhou,Peter Farrehi,Tamar S. Polonsky,Faraz S. Ahmad,Matthew T. Roe,Russell L. Rothman,Robert A. Harrington,Adrian F. Hernandez,William S. Jones +18 more
TL;DR: The ADAPTABLE trial as mentioned in this paper was a pragmatic randomized controlled trial that found no difference between high dose vs low dose aspirin for secondary prevention of ischemic or bleeding events, while concomitant P2Y12 inhibitor therapy modifies the effect of aspirin dose on clinical events.
1